Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over study of ceritinib in patients with ALK-positive malignancies previously enrolled in Novartis ceritinib trials
jRCT2080223056Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of ceritinib in Anaplastic Large Cell Lymphoma ALK-positive and ALK-positive non-small cell lung cancer, sponsored by Novartis. Started Dec 2015; status: completed.
02
Drugs
ceritinib
03
Conditions
Anaplastic Large Cell Lymphoma ALK-positiveALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on jRCT2080223056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223056.